Amyotrophic lateral sclerosis: therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice


Amyotrophic lateral sclerosis ( ALS ) is a rapidly progressing neurodegenerative disease that is characterized by motor neuron loss and that leads to paralysis and death 2-5 years after disease onset.

Nearly all patients with amyotrophic lateral sclerosis have aggregates of the RNA-binding protein TDP-43 in their brains and spinal cords, and rare mutations in the gene encoding TDP-43 can cause amyotrophic lateral sclerosis.

There are no effective TDP-43-directed therapies for amyotrophic lateral sclerosis or related TDP-43 proteinopathies, such as frontotemporal dementia.

Antisense oligonucleotides ( ASOs ) and RNA-interference approaches are emerging as attractive therapeutic strategies in neurological diseases.
Indeed, treatment of a rat model of inherited amyotrophic lateral sclerosis ( caused by a mutation in Sod1 ) with antisense oligonucleotides against Sod1 has been shown to substantially slow disease progression.

However, as SOD1 mutations account for only around 2-5% of ALS cases, additional therapeutic strategies are needed.
Silencing TDP-43 itself is probably not appropriate, given its critical cellular functions.

Researchers have presented a promising alternative therapeutic strategy for amyotrophic lateral sclerosis that involves targeting ataxin-2.
A decrease in ataxin-2 suppresses TDP-43 toxicity in yeast and flies, and intermediate-length polyglutamine expansions in the ataxin-2 gene increase risk of amyotrophic lateral sclerosis.

Researchers have used two independent approaches to test whether decreasing ataxin-2 levels could mitigate disease in a mouse model of TDP-43 proteinopathy.
First, they crossed ataxin-2 knockout mice with TDP-43 ( also known as TARDBP ) transgenic mice. The decrease in ataxin-2 reduced aggregation of TDP-43, markedly increased survival and improved motor function.
Second, in a more therapeutically applicable approach, they administered antisense oligonucleotides targeting ataxin-2 to the central nervous system of TDP-43 transgenic mice. This single treatment markedly extended survival. Because TDP-43 aggregation is a component of nearly all cases of amyotrophic lateral sclerosis, targeting ataxin-2 could represent a broadly effective therapeutic strategy. ( Xagena )

Becker LA et al, Nature 2017; Epub ahead of print

XagenaMedicine_2017



Indietro

Altri articoli

Interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral Mongersen ( GED-0301...


Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle deterioration and preferentially affects boys. Antisense-oligonucleotide-induced exon skipping allows synthesis...


Phase IIa clinical trial data on ATL1102 were published in the medical journal Neurology. The article highlights the successful outcomes...


Crohn’s disease-related inflammation is characterized by defective activity of the immunosuppressive cytokine transforming growth factor ( TGF )-beta1, due to...


On 13 December 2012, the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a negative opinion,...


The stability and propagation of hepatitis C virus ( HCV ) is dependent on a functional interaction between the HCV...


Dravet syndrome is a severe epilepsy syndrome characterized by infantile onset of therapy-resistant, fever-sensitive seizures followed by cognitive decline. Mutations...


A new type of treatment significantly reduces the severity of muscle weakness in myasthenia gravis, giving hope for a new...


Researchers have developed a successful strategy for interfering with Ebola virus infection that protected 75 percent of nonhuman primates exposed...